Treatment Trials

3 Clinical Trials for Various Conditions

Focus your search

      ACTIVE_NOT_RECRUITING
      Eribulin in Angiosarcoma and Epithelioid Hemangioendothelioma (EHE)
      Description

      This research study is studying a drug as a possible treatment for Angiosarcoma or Epithelioid hemangioendothelioma (EHE). -The drug involved in this study is Eribulin

      Conditions
      AngiosarcomaEpithelioid Hemangioendothelioma
      Talk to us
      RECRUITING
      A Study of BGC515 Capsules in Subjects With Advanced Solid Tumors
      Description

      The goal of this open-label, dose escalation and dose expansion Phase I clinical trial is to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of BGC515 administered once daily in 3 weeks cycles in solid tumor patients.

      Conditions
      MesotheliomaEpithelioid Hemangioendothelioma(EHE)Solid Tumor
      Talk to us
      TERMINATED
      Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects with Advanced Solid Tumors
      Description

      This is a Phase 1, first-in-human (FIH) clinical study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antitumor activity of IK-930, an oral TEAD inhibitor, administered orally (PO) as monotherapy in subjects with advanced solid tumors with or without gene alterations in the Hippo pathway for whom there are no further treatment options known to confer clinical benefit. The study consists of two phases, an initial Dose Escalation phase followed by a Dose Expansion phase.

      Conditions
      Solid Tumors, AdultSolid TumorMalignant Pleural Mesothelioma (MPM)Epithelioid Hemangioendothelioma (EHE)NF2 Deficient MesotheliomaOther NF2 Deficient Solid Tumors and Solid Tumors with YAP1/TAZ Fusion GenesNF2 DeficiencyYAP1 or TAZ Gene Fusions
      Talk to us